WO2004070022A2 - Use of oxalate deficient aspergillus niger strains for producing a polypeptide - Google Patents
Use of oxalate deficient aspergillus niger strains for producing a polypeptide Download PDFInfo
- Publication number
- WO2004070022A2 WO2004070022A2 PCT/EP2004/001173 EP2004001173W WO2004070022A2 WO 2004070022 A2 WO2004070022 A2 WO 2004070022A2 EP 2004001173 W EP2004001173 W EP 2004001173W WO 2004070022 A2 WO2004070022 A2 WO 2004070022A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- strain
- oxalate
- niger
- wild type
- enzyme
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/66—Aspergillus
- C12R2001/685—Aspergillus niger
Definitions
- the invention relates to oxalate deficient Aspergillus niger strains for producing a polypeptide, to their use and to a method for obtaining such strains.
- Oxalic acid is an undesirable by-product that accumulates in the culture supernatant of cells during fermentation and causes difficulties in the downstream processing of the desirable compound.
- -Ru2 RU2089615
- New strains of A. niger has properties of producer of citric acid and can be used in microbiological industry (DW1998-249164).
- -Ru3 The variability of A. niger, a producer of citric acid, under the influence of the separate and combined action of nitrosomethylurea and ultraviolet rays, E.Y.
- WO 00/50576 describes that oxaloacetate hydrolase deficient host cells can be used for producing desirable compounds, such as polypeptides, primary and secondary metabolites. These host cells have less oxaloacetate hydrolase activity than the parental cells they originate from.
- these oxaloacetate hydrolase (OAH) deficient cells produce less oxalic acid than the parental cells they originate from.
- This patent application does not show experimental data demonstrating that an oxaloacetate hydrolase deficient cell is a suitable polypeptide producer.
- Oxalate deficient A. niger strains suitable for the production of a given polypeptide or enzyme in an industrial setting have been isolated, wherein surprisingly the oxalate deficient strain produce at least the same amount of polypeptide or enzyme as the wild type strain they originate from under the same culture conditions. Preferably, the mutants produce at least the amount of polypeptide or enzyme the A. niger strain CBS 513.88 produces under the same culture condition.
- A. niger strain CBS 513.88 is taken as a reference of wild type oxalate levels obtainable in an A. niger culture, as a reference of wild type polypeptide level obtainable in an A. niger culture and as a reference of intracellular OAH activity obtainable in an A. niger culture.
- Oxalate deficient A. niger strains are defined as strains that produce less oxalate than the A. niger strain CBS 513.88 under the same culture conditions.
- the oxalate deficient A. niger strains used produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions. More preferably, the oxalate deficient A.
- the oxalate deficientA niger strains used produce no more than one fifth of the amount of oxalate that the wild type strain they originate from produces under the same culture conditions. More preferably, the oxalate deficient A. niger strains used produce no more than half the amount of oxalate that the A. niger strain CBS 513.88 produces under the same culture conditions. More preferably, the oxalate deficient A. n/gerstrains used produce no more than one third of the amount of oxalate that the A.
- the oxalate deficient A. niger strains used produce no more than one fifth of the amount of oxalate that theA niger strain CBS 513.88 produces under the same culture conditions.
- the oxalate deficient A. niger strain used has been obtained by applying the method defined later in this application.
- the oxalate deficient A niger strains of the invention are strains that produce more of a given polypeptide than the wld type strain they originate from under the same culture conditions. More preferably, the oxalate deficientA niger strain produces more of a given polypeptide than the A niger CBS 513.88 under the same culture conditions.
- Detection systems include any possible assay for detection of polypeptide or enzymatic activity.
- these assay systems include but are not limited to assays based on colorimetric, photometric, turbidimetric, viscosimetric, immunological, biological, chromatographic, and other available assays.
- the amount of active enzyme produced is determined by measurement of its activity in a model reaction (see examples).
- the oxalate deficient A. niger strains of the invention are strains having a detectable intracellular OAH activity as detected in a model reaction (see experimental information in the Examples) More preferably, the oxalate deficientA n/gerstrains of the invention are strains having an intracellular OAH activity, which is ranged between 0.1 and 100 % of the intracellular OAH activity of the wild type strain they originate from as detected in a model reaction, preferably between 0.5 and 90, more preferably between 0.5 and 80, even more preferably between 1 and 50, most preferably between 1 and 25 and even most preferably between 1 and 10.
- the oxalate deficient A niger strains have an intracellular OAH activity, which is ranged between 0.1 and 100% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction. More preferably, the oxalate deficient A n/ger strains of the invention are strains having an intracellular OAH activity, which is ranged between 1 and 90% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction.
- the oxalate deficientA niger strain of the invention is characterized by the fact that when this strain has been transformed with an expression construct comprising a gene coding for a polypeptide, said strain produces at least the amount of the polypeptide the wild type strain it originates from would produce under the same culture conditions, when the wild type strain has also been transformed with the same expression construct as the oxalate deficient strain.
- the gene coding for the polypeptide to be produced may be homologous or heterologous to the oxalate deficient A niger strain used.
- heterologous means that the polypeptide is not native to the A niger cell.
- the gene comprised in the expression construct is a heterologous gene for A niger.
- Preferred heterologous polypeptide is human serum albumine, lactoferrin, chymosin or Phospho ⁇ pase A2.
- the oxalate deficient strain has been transformed with a DNA construct comprising a DNA sequence encoding said polypeptide.
- the polypeptide is an enzyme. Enzymes that can be produced are carbohydrases, e.g.
- cellulases such as endoglucanases, ⁇ -glucanases, cellobiohydrolases or ⁇ -glucosideases, hemicellulases or pectinolytic enzymes such as xylanases, xylosidases, mannanases, galactanases, galactosidase, rhamnogalacturonases, arabanases, galacturonases, lyases, or amylolytic enzymes; phosphatases such as phytases, esterases such as lipases, proteolytic enzymes, oxidoreductases such as oxidases, transferases, or isomerases.
- the amylolytic enzyme to be produced is an alpha amylase (EC 3.2.1.1., alpha-1 ,4-glucan-4- glucano hydrolase or EC 3.2.1.2) . More, preferably, the DNA sequence encodes a fungal alpha amylase. Most preferably, the DNA sequence encoding the fungal alpha amylase is derived from A niger or Aspergillus oryzae. According to another embodiment, the enzyme to be produced is a proline specific endoprotease (EC 3.4.16.2). According to another embodiment, the enzyme to be produced is a phospholipase A1 (PLA1) (EC 3.1.1.32). More, preferably, the DNA sequence encodes a fungal PLA1. Most preferably, the DNA sequence encoding the fungal PLA1 is derived from Aspergillus niger or Aspergillus oryzae.
- PDA1 phospholipase A1
- the DNA sequence encoding the fungal PLA1 is derived from Asper
- the DNA sequence encoding the polypeptide to be produced may be operably linked to appropriate DNA regulatory regions to ensure a high level of expression of said DNA sequence and preferably a high secretion level of said polypeptide.
- the polypeptide to be produced is native to Aspergillus niger, its native secretion signal is preferably used.
- a fusion construct is preferably made comprising the glucoamylase gene of Aspergillus niger fused to the heterologous gene to be produced.
- the regulatory regions of the Aspergillus oryzae alpha amylase gene are used.
- the regulatory regions of the A niger glucoamylase gene are used.
- the alpha amylase secretion signals are used.
- the DNA construct may also comprise a selectable marker.
- the selectable marker may be present on a second DNA construct.
- these markers include but are not limited to amdS (acetamidase genes), auxotrophic marker genes such as argB, trpC, or pyrG and antibiotic resistance genes providing resistance against e.g. phleomycin, hygromycin B or G418.
- the marker gene is the acetamidase gene from Aspergillus nidulans.
- the acetamidase gene from Aspergillus nidulans is fused to the gpdA promoter. Transformation methods of A niger are well-known to the skilled person (Biotechnology of Filamentous fungi: Technology and Products. (1992) Reed Publishing (USA); Chapter 6: Transformation pages 113 to 156). The skilled person will recognize that successful transformation of A niger is not limited to the use of vectors, selection marker systems, promoters and transformation protocols specifically exemplified herein. After transformation, typically, the A niger population is cultivated on a solid medium in a petri dish. The transformants selected after culture on solid medium are typically cultivated in flask during three to seven days to check for expression of the polypeptide.
- a fed-batch fermentation process may be used for producing the polypeptide in the oxalate deficientA niger strain in an industrial setting.
- the polypeptide can be purified following techniques known to the skilled person. An example of such a recovery technique is explained in the following.
- the host When the fermentation is stopped, the host must be killed. This is accomplished by adding a killing-off agent at some specific temperature where this agent can work effectively.
- the killing-off agent may be natriumbenzoate or kaliumsorbate.
- the broth temperature is adjusted to the corresponding working temperature of this agent, by using classical cooling methods known to the skilled person.
- the separation of the cell material from the polypeptide is for example a simple filtration process: the fermentation broth is filtrated using a membrane filter press equipped with a textile cloth (membrane filter press and textile cloth can be obtained from Harborlite).
- a suitable filter-aid can be used, together with a suitable pre-coat of the filter cloth.
- the filtrate can be polished filtered on filter plates with an average pore size of typically 1-10 micron.
- filter plates with an average pore size of typically 1-10 micron.
- Several types of filter plates are known to the skilled person and are here suitable.
- a germ filtration may be carried out using a filter with a pore size of about 0.4 micrometer, to remove the major part of microorganisms.
- a pre-coat may be used to improve the filtration performance.
- the filtrate may be then concentrated by ultrafiltration (UF) with a factor of typically 10-25.
- UF membranes are suitable here.
- UF molecules with a typical molecular weight of less than a few thousands (depending also on the shape of the molecules) are removed from the filtrate.
- the relative amount of low molecular weight molecules to the polypeptide of interest may be reduced about 10-25 times after UF.
- the duration of the UF varies depending on the viscosity and filterability of the filtrate (which varies due to natural variations in the raw materials).
- the concentration of the polypeptide present in the ultrafiltrate is usually high enough to proceed with the formulation of the polypeptide into either a liquid or a dry formulation depending on the application contemplated.
- a method for obtaining oxalate deficientA n/ger strains which are suitable for producing high yields of a polypeptide and which can be used as polypeptide producers in an industrial setting.
- the polypeptide may be homologous or heterologous for said A niger.
- the wild type strain on which the method of the invention is applied may have been earlier transformed to express a gene coding for such polypeptide or enzyme as has been described earlier in the description.
- Such oxalate deficient A niger strains produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions.
- the oxalate deficient A niger strains produce more polypeptide than the wild type strain they originate from under the same culture conditions.
- the mutants produce at least the amount of polypeptide the A niger strain CBS 513.88 produced under the same culture condition. More preferably, the mutants produce more polypeptide than the A niger strain CBS 513.88 produced under the same culture conditions.
- This method comprises the following steps: a) A. niger is subjected to UV irradiation, b) MTP cultures of surviving colonies obtained in a) are realized c) a selection within the MTP cultures is performed in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions, d) a second selection is performed within the mutants obtained in step c) in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions.
- the method comprises the following steps: a) culture conditions are developed, which allow a production of at least 15 mM oxalate in microtiterplates (MTP) or at least 30 mM oxalate in flask culture in the fermentation medium at the end of fermentation, b) A niger is subjected to UV irradiation, c) MTP cultures of surviving colonies obtained in b) are realized under the culture conditions retained in a), d) a selection within the MTP cultures is performed in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions, e) a second selection is performed within the mutants obtained in step d) in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions.
- MTP microtiterplates
- the method comprises the following steps: a) culture conditions are developed, which allow a production of at least 15 mM oxalate in microtiterplates (MTP) or at least 30 mM oxalate in flask culture in the fermentation medium at the end of fermentation, b) A niger conidiospores are subjected to UV irradiation, c) MTP cultures of surviving colonies obtained in b) are realized under the culture conditions retained in a), d) a selection within the MTP cultures is performed in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions, e) a second selection is performed within the mutants obtained in step d) in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions.
- MTP microtiterplates
- the method comprises the following steps:
- a niger is subjected to UV irradiation, b) MTP cultures of surviving colonies obtained in a),are realized, c) a selection within the MTP cultures is performed in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions. d) a second selection is performed within the mutants obtained in c) in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions,
- colonies ofA niger are first cultivated in a medium which allows a production of at least 30 mM oxalate in MTP or at least 100 mM oxalate in flask culture in the fermentation medium at the end of fermentation.
- the fermentation time should be at least 3 days.
- the pH of this medium does not need to be manually corrected.
- the pH of the medium of this step is maintained between 3 and 7, preferably between 3,5 and 6,5, more preferably between 4 and 6. Most preferably the pH of this medium is maintained between pH 5 and 6. At such a pH value, the production of oxalate is known to be high.
- the pH of the medium is preferably buffered with a solution of 2-[N- Morpholinojethanesulfonic acid (MES) whose concentration is ranged between 0,1 and 1 M, more preferably between 0,15 and 0,55 M. Most preferably the MES concentration is 0,5 M.
- MES 2-[N- Morpholinojethanesulfonic acid
- the nitrogen source is a nitrogen source, which does not result in the acidification of the fermentation medium as a result of its uptake by the cell. More preferably, the nitrogen source of the medium of this step is urea.
- the medium used in this step is the flask defined medium 2 (FDM2) (see example 1 ).
- the A. niger strain used in this step is WT2 or the A niger strain CBS 513.88 (see experimental information).
- a niger is subjected to UV irradiation so that the survival percentage is ranged between 0,01% and 60%.
- the survival percentage is ranged between 0,05% and 50%. More preferably, the survival percentage is 0,1%.
- conidiospores is the preferred material to mutagenizeA niger by physical or chemical means. Mutants may however also be obtained from mycelium cells. The selection method described herein may be applied to select mutants obtained from either conidiospores or mycelium cells.
- MTP cultures of the surviving population obtained in a second step is performed during at least 3 days.
- mutants can be selected in a fourth step on basis of their oxalate production (oxalate selection step).
- mutants are selected that produce no more than one third of the amount of oxalate that the wild type strain they originate from produces under the same culture conditions. More preferably, mutants are selected that produce no more than one fifth of the amount of oxalate that the wild type strain they originate from produces under the same culture conditions.
- a second selection step which can be applied to the mutants before or after the oxalate selection step is the following: select mutants that produce at least the amount of polypeptide the wild type strains they originate from produce ur er the same culture conditions. Preferably, the mutants produce more of a given polypeptide than the wild type strains they originate from under the same culture conditions.
- the mutants produce at least the amourt of a given polypeptide the A niger strain CBS 513.88 produced under the same culture condition. More preferably, the mutants produce more of a given polypeptide than the A niger strain CBS 513.88 under the same culture conditions.
- the mutants obtained in the previous step and a wild type control are cultivated in liquid medium for at least three days in a suitable medium. Preferably, the cultivation is performed during at least five days.
- the amount of the polypeptide produced may be determined using a system for detection of said polypeptide as defined earlier on in the application.
- the polypeptide produced is an enzyme
- the amount of active enzyme produced is determined by measurement of its activity in a model reaction (see examples).
- An optional sixth step may be further applied to select for oxalate deficientA niger strains having an intracellular OAH activity which is detectable as detected in a model reaction.
- the model reaction is the one described in experimental information in the Examples. More preferably, this step allows the selection of oxalate deficientA n/ger strains having an intracellular OAH activity, which is ranged between 0.1 and 100 % of the intracellular OAH activity of the wild type strain they originate from as detected in a model reaction, preferably between 0.5 and 90, more preferably between 0.5 and 80, even more preferably between 1 and 50, most preferably between 1 and 25 and even most preferably between 1 and 10.
- the oxalate deficient A niger strains have an intracellular OAH activity, which is ranged between 0.1 and 100% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction. More preferably, the oxalate deficientA niger strains of the invention are strains having an intracellular OAH activity, which is ranged between 1 and 90% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction.
- the invention also relates to the use of an oxalate deficient A. niger strain for producing a given polypeptide. Accordingly, the invention also relates to a method for producing a given polypeptide wherein an oxalate deficient A.
- Such strain produces at least the same amount of said polypeptide as the wild type strain it originates from under the same culture conditions. Preferably, the strain produces more of said polypeptide than the wild type it originates from under the same culture conditions. According to another preferred embodiment, the strain produces at least the same amount of said polypeptide or enzyme as the CBS 513.88 A. niger strain under the same culture conditions. More preferably, the strain produces more of said polypeptide or enzyme than the CBS 513.88 A. niger strain under the same culture conditions.
- Figure 1 depicts the oxalate assay standard curve. The measured optical density is given as a function of the oxalate concentration present in solution.
- Figure 2 depicts the evolution of the pH of the culture supernatant of wild type A niger during fermentation in FDM1 medium with or without pH correction.
- Figure 3 depicts the average oxalate production obtained during fermentation of the wild type A niger in the FDM1 medium with or without pH correction.
- Figure 4 depicts the average oxalate production obtained during fermentation of the wild type A niger in the FDM1 medium as a function of the MES concentration, with ammonium or urea as nitrogen source, without pH correction.
- Figure 5 depicts the average oxalate production obtained during fermentation of the wild type A niger in the FDM2 medium without pH correction.
- Figure 6 depicts the pH evolution during fermentation of wild type and some selected oxalate deficient A niger in the MDM1 medium.
- Figure 7 depicts the average alpha amylase produced after fermentation in the FDM2 medium by the wild type and the 34 mutants as a function of their oxalate production.
- Figure 8 depicts the measured OAH activity in three oxalate deficient A niger mutants and in the wild type.
- Figure 9 depicts the average oxalate production obtained during the fermentation of the wild type and oxalate deficient A niger in the FDM2 medium without pH correction.
- Figure 10 depicts the residual glucose concentration present during fermentation of wild type and oxalate deficient A niger in the FDM 2 medium.
- Figure 1 1 depicts the pH evolution of culture supematants of wild type and oxalate deficient A. niger fermented in the FDM2 medium.
- Figure 12 depicts the evolution of the biomass produced during fermentation of the wild type and oxalate deficient A niger in the FDM2 medium.
- Figure 13 depicts the production of a praline specific endoprotease in WT1 and in FINAL (mutant 22) comprising the same estimated copy numbers of the gene coding for the proline specific endoprotease.
- Figure 14 depicts the production of phospholipase A1 in WT1 and in FINAL (mutant 22) in shake flask.
- WT 1 A. niger strain is used as a control for the level of oxalate,. the level of a given polypeptide and the level of intracellular OAH activity. This strain is deposited at the CBS Institute under the deposit number CBS 513.88.
- WT 2 WT 1 strain comprising several copies of an expression cassette comprising the A oryzae alpha-amylase gene integrated in the genome. This gene was already described elsewhere (Wirsel et al., (1989), Mol. Microbiol. 3:3-14). The original signal sequence coded by the A. oryzae alpha-amylase gene was replaced by the one of the glucoamylase gene from A niger. WT 2 was constructed and selected by techniques known to persons skilled in the art and described in EP 635 574 A1 and in WO 98/46772.
- MOPS Morpholino propanesulfonic acid
- the oxaloacetic solution was prepared by dissolving 0.053 g of oxaloacetic acid in 10 ml of the assay buffer. 50 ⁇ l of the suspension obtained after centrifugation was added to the preheated mix. OAH activity was determined according to the method described by Pedersen et al, 2000, Mol. Gen. Genet. 263:281-286. Briefly, oxaloacetate is used as substrate. The enzyme activity was determined from the rate of decrease of the absorbance (delta A/min) at 255 nm during 3 minutes with a time interval of 20 seconds and the absorption coefficient of oxaloacetate. The assay was carried out at 25°C.
- the protein content in the samples was determined according the Coomassie Plus Protein assay with Bovine Serum Albumin as a standard according to the manufacturer's instructions (Pierce, product number 23236).
- alpha amylase is given as an example of enzyme that can be produced by an oxalate deficient A niger strain at a level which is at least the same as the one produced by the parental strain the mutant originate from under the same culture conditions.
- Example 1 Method to make Oxalate deficient Aspergillus niger mutants which are high polypeptide producers are given as an example of enzyme that can be produced by an oxalate deficient A niger strain at a level which is at least the same as the one produced by the parental strain the mutant originate from under the same culture conditions.
- Oxalate deficient niger mutants were made starting from WT2.
- Cultures were performed at 34°C, in 96-wells microtiter plates (MTPs) or 300 ml flasks with one baffle in a rotary shaker at a shaking speed of 220 rpm.
- Flask precultures were inoculated with 17 000 spores per ml. 100 ml cultures were inoculated with 10 ml of preculture.
- Flask preculture medium 1 (FPM1), pH 5.5
- Flask defined medium 1 FDM1
- pH 6 Flask defined medium 1 (FDM1), pH 6
- Flask defined medium 2 (FDM2), pH 6: the FDM2 medium had the same composition as FDM1 except that 15 grams per liter urea are present instead of 15 grams per liter (NH 4 ) 2 SO 4 .
- This medium contained 100 grams per liter MES instead of 30 grams.
- Microtiter plate defined medium 1 (MDM1), pH 6
- the wild-type strain employed throughout this section is WT 1.
- the pH has been described as the most critical parameter for oxalate pioduction.
- the pH of A niger cultures should be maintained at a value close to 6 (Kubicek, C. P., et al, Appl. Environ. Microbiol. (1988) 54 , 633-637; and Ruijter, G. J. G., et al,. Microbiology (1999) 145, 2569-2576).
- Oxalate production sharply decreases for pH values below 4 (Ruijter, G. J. G., van de Vondervoort, P. J. I., and Visser, J. 1999. Microbiology 145, 2569-2576).
- a pH close to 6 can hardly be maintained in A niger cultures, because of the production of several organic acids by the fungus.
- triplicate flasks cultures were performed with a wild-type A niger strain, either with or without daily manual pH correction by addition of sterile sodium hydroxyde.
- a pre-culture phase of 48 hours in FPM1 medium was performed before FDM1 medium inoculation.
- 0.15 M MES (30 g IL) was present to buffer the medium acidification during A niger growth.
- the buffer present in the medium was not sufficient to counterbalance the production of organic acids by A. niger
- figure 3 shows that the oxalate yield was greatly affected by the pH of the culture. Cultures in which the pH was corrected yielded about 5 times mote oxalate than the cultures in which the pH was not corrected.
- a niger was grown in conditions yielding a maximal oxalate production, so that oxalate deficient strains could be selected and easily distinguished from a strain producing wild-type levels of oxalate.
- FDM1 1 M MES affected the growth of A niger and an intermediate concentration of 0.5 M MES was chosen.
- the growth medium finally chosen for flask cultivation during the screening was the FDM1 were the MES concentration was 0.5 M and where the ammonium sulfate was replaced by urea. From now on, that medium will be referred to as FDM2.
- FIG. 5 shows that in FDM2, the oxalate concentration reached wthout pH correction was equivalent to the oxalate concentration reached in FDM1 with pH correction (compare with figure 3). So, there was no need for pH correction anymore.
- a niger conidiospores were collected from WT 2 colonies sporulating on potato dextrose agar (PDA) medium (Difco, POTATO DEXTROSE AGAR, cultivation medium, catalogus. nr. 213400, year 1996-1997). 10 ml of a suspension containing 4x10 s conidiospores per ml was subjected to UV irradiation at 254 nm (Sylvania, 15 Watts Black Light Blue tube, model FT15T8/BLB) until an energy of 0,1783 J/crrt was received. A survival of 0.1% of the initial number of colonies was obtained.
- PDA potato dextrose agar
- the mutagenized spores solution was plated on PDA medium and 10 000 survivors were picked using a Genomic Solutions Flexys colony picker and further grown into 96 wells microtiter plates (MTP). These MTPs, called “masterplates” were incubated at 34°C until a strong sporulation was apparent. The masterplates were replica plated using the Genomic Solutions Flexys colony picker into MTPs containing 40 ⁇ l of FPM1 and incubated for 48 hours at 34°C. 170 ⁇ l of MDM1 was then added and the MTPs were further incubated for 7 days at 34°C.
- the supernatant of the 10 000 individual cultures was assayed for the presence of oxalate.
- the oxalate concentration reached in cultures of the WT 1 and WT 2 strains was in the range of 40 mM.
- the mutants for which the oxalate concentration in the growth medium was below 12 mM were selected for a further selection round. 255 mutants were retained. This second selection round was more stringent than the first one, so that it allowed to get rid of false positives.
- the second mutant selection consisted of a quadruplicate MTP cultivation and assay for oxalate.
- the conditions employed were the same as the ones described here above.
- Table 5, second column below lists the oxalate concentration reached in the lowest producers amongst the mutants and in wild-type MTP cultures.
- 1 U/ml is the quantity of alpha amylase needed to convert 1 g soluble starch per hour into a product.
- the formation of this product is being measured by following the absorption at 620 nm after addition of iode at pH 5.5 and at 30° C.
- the incubation time with iode is between 15 and 25 minutes.
- Figure 6 shows that the selected mutant strains acidify less the MDM1 growth medium upon growth compared to the wild-type strains. 5. Second selection: alpha amylase production
- the 34 mutants obtained in the former paragraph were subsequently selected as to their capacities to produce alpha amylase.
- the 34 mutants and WT2 were grown the same way as in the former paragraph, and characterized as to their alpha-amylase production.
- the alpha-amylase activity present in culture supernatants was determined using the alpha amylase assay kit from Megazyme (Megazyme, CERALPHA alpha amylase assay kit, catalogus. ref. K-CERA, year 2000-2001).
- Table 5 third column lists the average alpha amylase production detected in WT2 and in the 34 mutants.
- Figure 7 depicts the average production of alpha amylase as a function of the oxalate production of the 34 mutants and the wild type. It could be observed in table 5, third column and in figure 7 that all the 34 mutants produced significantly more alpha-amylase than the wild-type strain they originated from. All the oxalate mutants found at the former paragraph were retained as mutants able to produce at least the same amount of enzyme as the wild type they originate from under the same culture conditions. Mutants 15, 19 and 22 were selected for further selection.
- the intracellular OAH activity was measured in the three mutants (15, 19, 22) selected at the former paragraph and as a control in WT1 and WT2. For some strains, measurements were made twice (A, B) as indicated in figure 8. The test developed to measure OAH activity is described in experimental data. Mutants 15 and 22 showed a detectable OAH activity (figure 8): approximatively 10 to 20 % of the WT 1 or WT2. Surprisingly mutant 19 showed a high OAH activity, which is similar to the one of WT2. Surprisingly, these three oxalate deficient mutants still have a relative high OAH activity. Furthermore, they also have good enzyme production capacities.
- Example 2 Example 2
- FPM1 and FDM2 media as defined in example 1.
- Mutants 18, 22, 15, 23, 19, 33 were grown in the FDM2 medium, after 48 hours of preculture phase in FPM1 , and characterized as to their oxalate production, and several growth parameters (residual glucose, pH and biomass formed).
- the results obtained with the FDM2 medium confirmed the low level of oxalate production of the mutants compared to the wild-type strains (figure 9).
- the residual glucose present in the FDM2 medium during growth of wild type and mutant strains was assayed using the Glucose assay kit from Sigma Diagnostics (Sigma, GLUCOSE diagnostic kit, catalogus nr. 510-A, year 2000-2001 ). As can be seen in figure 10, the glucose was almost completely consumed in some mutant cultures after 7 days of growth, suggesting the low oxalate level found in the selected mutant did not reflect a low metabolic activity. Only mutant 23 seemed to have a reduced metabolic activity.
- the biomass formation was followed by weighing the biomass dry weight formed in the cultures at various cultivation times. Flasks were sacrificed at each time interval considered and the total biomass dry weight content of the flask was determined.
- mutants showed various growth profiles but tended to reach the same biomass level as the parental strain WT 2 after 7 days of cultivation.
- Mutant 23 was the only one which shown a low level of biomass formation, but this level was still comparable to the one reached by the wild-type strain WT 1 from which WT 2 originated.
- Mutant 23 was not retained as oxalate deficient mutant for further characterization.
- the sporulation capacities of the mutants were visually evaluated. It was found that the sporulation level of the mutants was comparable to the one of the wild type strain they originate from. Only one mutant seemed to have lower sporulation capacities.
- mutant 22 was used as oxalate deficientA niger strain for producing different enzymes.
- This mutant was obtained from WT2 and earlier on from WT1.
- all the copies of the alpha amylase gene were deleted according to the method described in EP 635 574 A, using the acetamidase gene as selection marker gene.
- This mutant empty of any foreign enzyme encoding gene would be named FINAL in the following examples.
- FINAL was transformed with expression construct comprising the gene coding for the corresponding enzyme to be expressed as described in the following examples.
- the expression constructs introduced in FINAL were also introduced in WT1 as described in the following examples. Copy number was checked. Mutant 22 was tested and compared to WT1 for the production of a proline specific endoprotease and PLA1. Mutant 22 produced the same amount of all enzymes tested as the WT1 it originates from under the same culture conditions or even more.
- the proteolytic activity of the proline specific endoprotease was spectrophotometrically measured in time at pH 5 and about 37°C using Z-Gly(cine)- Pro(line)-pNA as a substrate.
- 1 U proline specific endoprotease is defined as the amount of enzyme which converts 1 micromol Z-Gly(cine)-Pro(line)-pNA per min at pH 5 and at 37°C.
- Figure 13 shows that the proline specific endoprotease activity of the A niger transformants with different estimated copy number is comprised in a range from 42 to 135 U/l. Strains with one estimated copy number have an activity of 42- 46 U/l and correlates well with the activity of two and three copy strains. We concluded that FINAL produces at least the same amount of proline specific endoprotease as WT1 under the same culture conditions.
- PLA1 phospholipase A1
- PLA1 hydrolyses the sulphide bond at the A1 position, dissociating thio-octano ⁇ c acid.
- Thio-octano ⁇ c acid reacts with 4,4 dithiopyridine (color reagent, 4-DTDP), forming 4- thiopyridone.
- 4-Thiopyridone is in tautomeric equilibrium with 4-mercaptopyridine, which absorbs radiation having a wavelength of 334 nm. The extinction change at that wavelength is measured.
- One unit is the amount of enzyme that liberates of 1 nmol thio-octano ⁇ c acid from 1 ,2-dithiodioctanoyl phosphatidylcholine per minute at 37°C and pH 4.0.
- the substrate solution is prepared by dissolving 1 g diC8 crystals per 66 ml ethanol and add 264 ml acetate buffer.
- the acetate buffer comprises 0.1 M Acetate buffer pH 3.85 containing 0.2% Triton-X100.
- the colour reagent is a 11 mM 4,4-dithiodipyridine solution. It was prepared by weighting 5,0 mg 4,4-dithiodipyridine in a 2 ml eppendorf sample cup and dissolving in 1.00 ml ethanol. 1.00 ml of milli-Q water was added. The results are depicted in figure 14. It is shown that PLA1 activity in transformants of WT1 cultures decreased after 4-5 days. However, the PLA1 activity of transformants of FINAL accumulates during fermentation and no decrease in activity could be observed. We concluded that FINAL produces more PLA1 than the wild type counterpart it originates from under the same culture conditions.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04708360A EP1590444A2 (en) | 2003-02-05 | 2004-02-05 | Use of oxalate deficient aspergillus niger strains for producing a polypeptide |
AU2004209618A AU2004209618B2 (en) | 2003-02-05 | 2004-02-05 | Use of oxalate deficient aspergillus niger strains for producing a polypeptide |
CA002513833A CA2513833A1 (en) | 2003-02-05 | 2004-02-05 | Use of oxalate deficient aspergillus niger strains for producing a polypeptide |
JP2006501780A JP2006516399A (en) | 2003-02-05 | 2004-02-05 | Use of an oxalate-deficient Aspergillus niger strain for the production of polypeptides |
US10/544,207 US20060127976A1 (en) | 2003-02-05 | 2004-02-05 | Use of oxalate deficient aspergillus niger strains for producing a polypeptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03100236.3 | 2003-02-05 | ||
EP03100236 | 2003-02-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004070022A2 true WO2004070022A2 (en) | 2004-08-19 |
WO2004070022A3 WO2004070022A3 (en) | 2004-10-28 |
Family
ID=32842807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/001173 WO2004070022A2 (en) | 2003-02-05 | 2004-02-05 | Use of oxalate deficient aspergillus niger strains for producing a polypeptide |
Country Status (7)
Country | Link |
---|---|
US (1) | US20060127976A1 (en) |
EP (1) | EP1590444A2 (en) |
JP (1) | JP2006516399A (en) |
CN (1) | CN1836033A (en) |
AU (1) | AU2004209618B2 (en) |
CA (1) | CA2513833A1 (en) |
WO (1) | WO2004070022A2 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010122141A1 (en) | 2009-04-24 | 2010-10-28 | Dsm Ip Assets B.V. | Carbohydrate degrading polypeptide and uses thereof |
WO2010121933A1 (en) | 2009-04-22 | 2010-10-28 | Dsm Ip Assets B.V. | Process for the production of a recombinant polypeptide of interest |
WO2011009700A1 (en) | 2009-07-22 | 2011-01-27 | Dsm Ip Assets B.V. | Improved host cell for the production of a compound of interest |
WO2011098577A1 (en) | 2010-02-11 | 2011-08-18 | Dsm Ip Assets B.V. | Host cell capable of producing enzymes useful for degradation of lignocellulosic material |
WO2011098580A1 (en) | 2010-02-11 | 2011-08-18 | Dsm Ip Assets B.V. | Polypeptide having cellobiohydrolase activity and uses thereof |
WO2012000887A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having swollenin activity and uses thereof |
WO2012000890A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having beta-glucosidase activity and uses thereof |
WO2012000892A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof |
WO2012000891A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having carbohydrate degrading activity and uses thereof |
WO2012000886A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having beta-glucosidase activity and uses thereof |
WO2012000888A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having acetyl xylan esterase activity and uses thereof |
EP2410048A1 (en) | 2005-01-24 | 2012-01-25 | DSM IP Assets B.V. | Method for producing a compound of interest in a filamentous fungal cell |
EP2423315A1 (en) | 2006-06-29 | 2012-02-29 | DSM IP Assets B.V. | A method for achieving improved polypeptide expression |
EP2458007A1 (en) | 2005-11-29 | 2012-05-30 | DSM IP Assets B.V. | DNA binding site of a transcriptional activator useful in gene expression |
WO2012123429A1 (en) | 2011-03-11 | 2012-09-20 | Dsm Ip Assets B.V. | Vector-host system |
EP2511372A1 (en) | 2006-11-02 | 2012-10-17 | DSM IP Assets B.V. | Improved production of secreted proteins by filamentous fungi |
EP2631295A2 (en) | 2007-02-15 | 2013-08-28 | DSM IP Assets B.V. | A recombinant host cell for the production of a compound of interest |
WO2014013074A1 (en) | 2012-07-19 | 2014-01-23 | Dsm Ip Assets B.V. | Agse-deficient strain |
WO2014044782A1 (en) | 2012-09-19 | 2014-03-27 | Dsm Ip Assets B.V. | Cell modification method using essential genes as markers and optionally recycling these |
WO2015082488A1 (en) | 2013-12-02 | 2015-06-11 | Dsm Ip Assets B.V. | Ice structuring protein |
WO2016110453A1 (en) | 2015-01-06 | 2016-07-14 | Dsm Ip Assets B.V. | A crispr-cas system for a filamentous fungal host cell |
WO2016193292A1 (en) | 2015-06-02 | 2016-12-08 | Dsm Ip Assets B.V. | Use of ice structuring protein afp19 expressed in filamentous fungal strains for preparing food |
WO2018166943A1 (en) | 2017-03-13 | 2018-09-20 | Dsm Ip Assets B.V. | Zinc binuclear cluster transcriptional regulator-deficient strain |
WO2019215078A1 (en) | 2018-05-07 | 2019-11-14 | Dsm Ip Assets B.V. | Process for enzymatic oil degumming |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8637280B2 (en) | 2005-12-01 | 2014-01-28 | Adcuram Nutrition Holding Gmbh | Genes useful for the industrial production of citric acid |
MX2018001687A (en) * | 2015-08-10 | 2019-06-06 | Parabel Ltd | Methods and systems for extracting reduced oxalic acid protein from aquatic species and compositions thereof. |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4518697A (en) * | 1981-12-14 | 1985-05-21 | Henkel Kommanditgesellschaft Auf Aktien | Acid stable protease from mutants of genus Aspergillus |
WO1997010350A1 (en) * | 1995-09-11 | 1997-03-20 | Likospol S.R.O. | Process, apparatus and microorganism strain for the manufacture of citric acid |
WO2000050576A1 (en) * | 1999-02-22 | 2000-08-31 | Novozymes A/S | Oxaloacetate hydrolase deficient fungal host cells |
US6432672B1 (en) * | 1997-04-11 | 2002-08-13 | Gerardus Cornelis Maria Selten | Gene conversion as a tool for the construction of recombinant industrial filamentous fungi |
-
2004
- 2004-02-05 US US10/544,207 patent/US20060127976A1/en not_active Abandoned
- 2004-02-05 EP EP04708360A patent/EP1590444A2/en not_active Ceased
- 2004-02-05 WO PCT/EP2004/001173 patent/WO2004070022A2/en active Application Filing
- 2004-02-05 AU AU2004209618A patent/AU2004209618B2/en not_active Ceased
- 2004-02-05 CA CA002513833A patent/CA2513833A1/en not_active Abandoned
- 2004-02-05 CN CNA2004800036436A patent/CN1836033A/en active Pending
- 2004-02-05 JP JP2006501780A patent/JP2006516399A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4518697A (en) * | 1981-12-14 | 1985-05-21 | Henkel Kommanditgesellschaft Auf Aktien | Acid stable protease from mutants of genus Aspergillus |
WO1997010350A1 (en) * | 1995-09-11 | 1997-03-20 | Likospol S.R.O. | Process, apparatus and microorganism strain for the manufacture of citric acid |
US6432672B1 (en) * | 1997-04-11 | 2002-08-13 | Gerardus Cornelis Maria Selten | Gene conversion as a tool for the construction of recombinant industrial filamentous fungi |
WO2000050576A1 (en) * | 1999-02-22 | 2000-08-31 | Novozymes A/S | Oxaloacetate hydrolase deficient fungal host cells |
Non-Patent Citations (4)
Title |
---|
HOMBERGH VAN DEN J P T W ET AL: "NEW PROTEASE MUTANTS IN ASPERGILLUS NIGER RESULTS IN STRONGLY REDUCED IN VITRO DEGRADATION OF TARGET PROTEINS;GENETICAL AND BIOCHEMICAL CHARACTERIZATION OF SEVEN COMPLEMENTATION GROUPS" CURRENT GENETICS, NEW YORK, NY, US, vol. 28, no. 4, 1995, pages 299-308, XP000867320 ISSN: 0172-8083 * |
PEDERSEN H ET AL: "Construction and characterization of an oxalic acid nonproducing strain of Aspergillus niger." METABOLIC ENGINEERING. UNITED STATES JAN 2000, vol. 2, no. 1, January 2000 (2000-01), pages 34-41, XP002286173 ISSN: 1096-7176 cited in the application * |
RUIJTER G J G ET AL: "OXALIC ACID PRODUCTION BY ASPERGILLUS NIGER: AN OXALATE-NON-PRODUCING MUTANT PRODUCES CITRIC ACID AT PH 5 AND IN THE PRESENCE OF MANGANESE" MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 145, no. 9, September 1999 (1999-09), pages 2569-2576, XP000905457 ISSN: 1350-0872 * |
SARANGBIN S ET AL: "Yam bean starch: a novel substrate for citric acid production by the protease-negative mutant strain of Aspergillus niger" CARBOHYDRATE POLYMERS, APPLIED SCIENCE PUBLISHERS, LTD. BARKING, GB, vol. 38, no. 3, March 1999 (1999-03), pages 219-224, XP004154847 ISSN: 0144-8617 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2410048A1 (en) | 2005-01-24 | 2012-01-25 | DSM IP Assets B.V. | Method for producing a compound of interest in a filamentous fungal cell |
EP2458008A1 (en) | 2005-11-29 | 2012-05-30 | DSM IP Assets B.V. | DNA binding site of a transcriptional activator useful in gene expression |
EP2458007A1 (en) | 2005-11-29 | 2012-05-30 | DSM IP Assets B.V. | DNA binding site of a transcriptional activator useful in gene expression |
EP2423315A1 (en) | 2006-06-29 | 2012-02-29 | DSM IP Assets B.V. | A method for achieving improved polypeptide expression |
EP2511372A1 (en) | 2006-11-02 | 2012-10-17 | DSM IP Assets B.V. | Improved production of secreted proteins by filamentous fungi |
EP2631295A2 (en) | 2007-02-15 | 2013-08-28 | DSM IP Assets B.V. | A recombinant host cell for the production of a compound of interest |
WO2010121933A1 (en) | 2009-04-22 | 2010-10-28 | Dsm Ip Assets B.V. | Process for the production of a recombinant polypeptide of interest |
WO2010122141A1 (en) | 2009-04-24 | 2010-10-28 | Dsm Ip Assets B.V. | Carbohydrate degrading polypeptide and uses thereof |
EP3293264A1 (en) | 2009-07-22 | 2018-03-14 | DSM IP Assets B.V. | Improved host cell for the production of a compound of interest |
WO2011009700A1 (en) | 2009-07-22 | 2011-01-27 | Dsm Ip Assets B.V. | Improved host cell for the production of a compound of interest |
US11753631B2 (en) | 2010-02-11 | 2023-09-12 | Versalis S.P.A. | Host cell capable of producing enzymes useful for degradation of lignocellulosic material |
US10035999B2 (en) | 2010-02-11 | 2018-07-31 | Dsm Ip Assets B.V. | Host cell capable of producing enzymes useful for degradation of lignocellulosic material |
US10077435B2 (en) | 2010-02-11 | 2018-09-18 | Dsm Ip Assets B.V. | Host cell capable of producing enzymes useful for degradation of lignocellulosic material |
US10920207B2 (en) | 2010-02-11 | 2021-02-16 | Dsm Ip Assets B.V. | Host cell capable of producing enzymes useful for degradation of lignocellulosic material |
AU2011214324B2 (en) * | 2010-02-11 | 2014-11-20 | Dsm Ip Assets B.V. | Host cell capable of producing enzymes useful for degradation of lignocellulosic material |
US9738881B2 (en) | 2010-02-11 | 2017-08-22 | Dsm Ip Assets B.V. | Host cell capable of producing enzymes useful for degradation of lignocellulosic material |
WO2011098580A1 (en) | 2010-02-11 | 2011-08-18 | Dsm Ip Assets B.V. | Polypeptide having cellobiohydrolase activity and uses thereof |
CN102762727A (en) * | 2010-02-11 | 2012-10-31 | 帝斯曼知识产权资产管理有限公司 | Host cell capable of producing enzymes useful for degradation of lignocellulosic material |
WO2011098577A1 (en) | 2010-02-11 | 2011-08-18 | Dsm Ip Assets B.V. | Host cell capable of producing enzymes useful for degradation of lignocellulosic material |
CN102762727B (en) * | 2010-02-11 | 2016-07-20 | 帝斯曼知识产权资产管理有限公司 | The host cell of the enzyme for lignocellulose degradation material can be produced |
US9109214B2 (en) | 2010-02-11 | 2015-08-18 | Dsm Ip Assets B.V. | Host cell capable of producing enzymes useful for degradation of lignocellulosic material |
WO2012000891A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having carbohydrate degrading activity and uses thereof |
WO2012000888A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having acetyl xylan esterase activity and uses thereof |
WO2012000887A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having swollenin activity and uses thereof |
WO2012000890A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having beta-glucosidase activity and uses thereof |
WO2012000892A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof |
WO2012000886A1 (en) | 2010-06-29 | 2012-01-05 | Dsm Ip Assets B.V. | Polypeptide having beta-glucosidase activity and uses thereof |
WO2012123429A1 (en) | 2011-03-11 | 2012-09-20 | Dsm Ip Assets B.V. | Vector-host system |
WO2014013074A1 (en) | 2012-07-19 | 2014-01-23 | Dsm Ip Assets B.V. | Agse-deficient strain |
WO2014044782A1 (en) | 2012-09-19 | 2014-03-27 | Dsm Ip Assets B.V. | Cell modification method using essential genes as markers and optionally recycling these |
WO2015082488A1 (en) | 2013-12-02 | 2015-06-11 | Dsm Ip Assets B.V. | Ice structuring protein |
WO2016110453A1 (en) | 2015-01-06 | 2016-07-14 | Dsm Ip Assets B.V. | A crispr-cas system for a filamentous fungal host cell |
WO2016193292A1 (en) | 2015-06-02 | 2016-12-08 | Dsm Ip Assets B.V. | Use of ice structuring protein afp19 expressed in filamentous fungal strains for preparing food |
WO2018166943A1 (en) | 2017-03-13 | 2018-09-20 | Dsm Ip Assets B.V. | Zinc binuclear cluster transcriptional regulator-deficient strain |
WO2019215078A1 (en) | 2018-05-07 | 2019-11-14 | Dsm Ip Assets B.V. | Process for enzymatic oil degumming |
Also Published As
Publication number | Publication date |
---|---|
AU2004209618B2 (en) | 2008-04-17 |
US20060127976A1 (en) | 2006-06-15 |
CA2513833A1 (en) | 2004-08-19 |
CN1836033A (en) | 2006-09-20 |
AU2004209618A1 (en) | 2004-08-19 |
WO2004070022A3 (en) | 2004-10-28 |
JP2006516399A (en) | 2006-07-06 |
EP1590444A2 (en) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004209618B2 (en) | Use of oxalate deficient aspergillus niger strains for producing a polypeptide | |
US9322045B2 (en) | Host cell for the production of a compound of interest | |
EP1266011B1 (en) | Fungal transcriptional activator useful in methods for producing polypeptides | |
MX2011009059A (en) | Method for improving the yield of a polypeptide. | |
US20100112638A1 (en) | Recombinant host cell for the production of a compound of interest | |
JP2018504936A (en) | Fungal strains and methods of use | |
AU2005254734A1 (en) | Production of polypeptides by improved secretion | |
JP2002539793A (en) | Promoters for expressing genes in fungal cells | |
JP4563585B2 (en) | Fungal transcriptional activators useful in polypeptide production methods | |
JP2019503168A (en) | Method for producing a protein in a filamentous fungus with reduced CLR2 activity | |
US20130189733A1 (en) | Production of secreted proteins by filamentous fungi | |
JP2019501646A (en) | Method for producing a protein in a filamentous fungus with reduced CLR1 activity | |
US8298787B2 (en) | Methods for enhancing a secretion efficiency of recombinant foreign protein in yeast expression system | |
WO2011095374A2 (en) | Process for preparing filamentous fungal strains having a sexual cycle and a process for preparing sexually crossed filamentous fungal strains | |
JP4756125B2 (en) | Novel mutants and selectable markers of Aspergillus oryzae | |
EP4023757A1 (en) | Methods for generating selection marker-free transformants of heterokaryotic organisms | |
US20220267783A1 (en) | Filamentous fungal expression system | |
KR20020059350A (en) | Use of aspergillus sojae as host for recombinant protein producion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004209618 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2513833 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004708360 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006501780 Country of ref document: JP Ref document number: 20048036436 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004209618 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2006127976 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10544207 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004708360 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10544207 Country of ref document: US |